Xenon Pharmaceuticals (XENE) Current Deferred Revenue (2013 - 2021)

Xenon Pharmaceuticals (XENE) has 6 years of Current Deferred Revenue data on file, last reported at $2.2 million in Q3 2021.

• On a quarterly basis, Current Deferred Revenue fell 70.43% year-over-year to $2.2 million in Q3 2021; TTM through Sep 2021 was $2.2 million, a 70.43% decrease from a year earlier, with the FY2020 full-year figure at $3.6 million, down 87.76% from the prior year.
• Current Deferred Revenue for Q3 2021 stood at $2.2 million, down from $3.0 million in the prior quarter.
• Over the last five years, Current Deferred Revenue for XENE reached as high as $29.7 million in Q4 2019 and fell as low as $2.2 million in Q3 2021.
• Historically, Current Deferred Revenue has averaged $10.9 million across 3 years, with a median of $5.5 million in 2020.
• Across the five-year window, Current Deferred Revenue slumped 87.76% in 2020 and plunged 70.43% in 2021, its largest moves.
• Year by year, Current Deferred Revenue stood at $29.7 million in 2019, then slumped by 87.76% to $3.6 million in 2020, then sank by 39.54% to $2.2 million in 2021.
• Per Business Quant data, the three most recent Current Deferred Revenue figures were $2.2 million in Q3 2021, $3.0 million in Q2 2021, and $3.6 million in Q1 2021.